MAPT and Alzheimer disease: Lastly, we utilized longitudinal tau-PET and longitudinal cognitive data from a subset of 290 subjects to determine whether αSyn co-pathology specifically accelerates Aβ-related tau aggregation rates and cognitive decline over time in AD patients.